Case report: Dramatic response to pralsetinib in an elderly patient with advanced RET-fusion positive papillary thyroid carcinoma

We are recently faced with a progressive evolution of the therapeutic paradigm for radioiodine refractory differentiated thyroid cancer (RAI-R DTC), since the advent of tissue agnostic inhibitors. Thus, tumor genotype assessment is always more relevant and is playing a crucial role into clinical pra...

Szczegółowa specyfikacja

Opis bibliograficzny

Główni autorzy:	Margherita Nannini, Andrea Repaci, Gianluca Ricco, Manuela Ianni, Arber Golemi, Vincenzo Maiolo, Marco Ferrari, Filippo Natali, Elisa Lodi Rizzini, Fabio Monari, Erica Solaroli, Antonio De Leo, Thais Maloberti, Maria A. Pantaleo, Dario De Biase, Giovanni Tallini
Format:	Artigo
Język:	Inglês
Wydane:	Frontiers Media S.A. 2022-12-01
Seria:	Frontiers in Oncology
Hasła przedmiotowe:	differentiated thyroid cancer papillary thyroid carcinoma RET RET-rearrangement RET-inhibitor pralsetinib
Dostęp online:	https://www.frontiersin.org/articles/10.3389/fonc.2022.1042525/full
Etykiety:	Dodaj etykietę Nie ma etykietki, Dołącz pierwszą etykiete!